Dan Rosenblum has been a full-time stock trader since 1999 after leaving a job at a publicly held medical-device company. Rosenblum joined SharkInvesting.com that year and has been the online trading community's resident biotech expert ever since. Rosenblum writes the SharkBiotech.com newsletter, which has outperformed the S&P 500 and the Nasdaq Biotechnology Index every year since its inception in 2006. Rosenblum lives with his wife and kids in Rockland County, New York.
I think the market is obsessing over the Alexion negatives and not looking at the real potential for positive catalysts ahead.
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.
Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.
The exon-skipping drug technology is worth a lot more than just eteplirsen alone.
Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.
TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.
Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.
Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.
TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.